Ustekinumab Plus UVB-311nm Half-side Phototherapy in Patients With Psoriasis.

Trial Profile

Ustekinumab Plus UVB-311nm Half-side Phototherapy in Patients With Psoriasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2012

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2012 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Mar 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00870285).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top